SF3B1 and myelodysplastic syndrome: Thus, in the WHO 2017 the SF3B1 mutation is integrated into the diagnosis of MDS-RS (diagnostic criteria: RS ≥ 15% or RS ≥ 5% if SF3B1mut) [1].